Media stories about Insmed (NASDAQ:INSM) have been trending somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Insmed earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.1970196639091 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- Radar for In Play Stock – Insmed Incorporated (NASDAQ: INSM) (stockspen.com)
- Hot Stock’s Alert – Insmed Incorporated (NASDAQ: INSM) (alphabetastock.com)
- Volatile Stock in Focus – Insmed Incorporated (NASDAQ: INSM) (stockspen.com)
- Insmed Incorporated (INSM) stock is worth at $23.77 (nasdaqfortune.com)
- Insmed Research Award Created for Non-Tuberculosis Mycobacteria Lung Disease Projects (bronchiectasisnewstoday.com)
INSM opened at $23.62 on Thursday. Insmed has a one year low of $11.49 and a one year high of $33.94. The stock has a market capitalization of $1,825.93, a PE ratio of -8.17 and a beta of 1.11. The company has a current ratio of 8.72, a quick ratio of 8.72 and a debt-to-equity ratio of 0.15.
Insmed (NASDAQ:INSM) last released its quarterly earnings results on Friday, February 23rd. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.18). research analysts expect that Insmed will post -3.8 earnings per share for the current year.
A number of equities research analysts have issued reports on INSM shares. Zacks Investment Research lowered Insmed from a “hold” rating to a “sell” rating in a research report on Wednesday, February 28th. Morgan Stanley started coverage on Insmed in a research report on Wednesday, March 21st. They issued an “overweight” rating and a $39.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Insmed in a research report on Thursday, January 4th. BidaskClub lowered Insmed from a “hold” rating to a “sell” rating in a research report on Tuesday, March 20th. Finally, Robert W. Baird reaffirmed a “positive” rating and issued a $42.00 price target (up previously from $32.00) on shares of Insmed in a research report on Thursday, January 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $36.90.
COPYRIGHT VIOLATION NOTICE: “Insmed (INSM) Given Coverage Optimism Rating of 0.16” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/04/19/insmed-insm-given-coverage-optimism-rating-of-0-16-2.html.
Insmed Company Profile
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.